Lin Gen, Wang Yongsheng, Xin Tao, Zhang Ding, Zhang Qiuyu, Li Yangsi, Chi Yudan, Fan Yun, Liu Anwen, Xu Haipeng, Shi Liang, Zhang Longfeng, Miao Qian, Zheng Xiaobin, Li Lijun, Zhou Kaijia, Yao Qiwei, Zou Zihua, Miao Kang, Hong Yaping
Department of Medical Oncology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, Beijing, China.
Division of Thoracic Tumor Multimodality Treatment, Cancer Center and National Medical Products Administration key Laboratory for Clinical Research and Evaluation of Innovative Drugs, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Thorac Cancer. 2025 Jun;16(11):e70088. doi: 10.1111/1759-7714.70088.
Lung cancer patients with leptomeningeal metastases (LMs) suffer from severe clinical symptoms, poor quality of life, narrow diagnostic and therapeutic time windows, low response to standard treatments, short survival periods, and poor prognoses. At present, there is a lack of precise diagnosis and treatment pathways and relevant consensus for LMs of lung cancer. In order to better guide the clinical diagnosis and treatment of LMs of lung cancer in an early, reasonable, and safe way, the experts of the Neurological Tumor Specialist Committee of the Chinese Society of Clinical Oncology (CSCO) have formulated this consensus based on the actual diagnosis and treatment of LMs of lung cancer in China, with reference to the latest research data, relevant guidelines and consensus, and the experts' clinical experience, as well as the results of experts' polling on the pre-set issues of LMs. The consensus focuses on diagnosing LMs, stratified management, efficacy evaluation systems, treatment strategies, common complications, and palliative care. It gives recommendations in each of the five aspects to provide clinicians with suggestions and references for diagnosing and treating LMs in lung cancer.
患有软脑膜转移（LM）的肺癌患者会出现严重的临床症状、生活质量差、诊断和治疗时间窗狭窄、对标准治疗反应低、生存期短以及预后不良。目前，肺癌LM缺乏精确的诊断和治疗路径以及相关共识。为了以早期、合理和安全的方式更好地指导肺癌LM的临床诊断和治疗，中国临床肿瘤学会（CSCO）神经肿瘤专家委员会的专家们参考最新研究数据、相关指南和共识、专家临床经验以及专家对LM预设问题的投票结果，基于中国肺癌LM的实际诊断和治疗情况制定了本共识。该共识聚焦于LM的诊断、分层管理、疗效评估体系、治疗策略以及常见并发症和姑息治疗。它在这五个方面分别给出了建议，为临床医生诊断和治疗肺癌LM提供建议和参考。
